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Abstract
Reengineering the receptor footprints of adeno-associated virus (AAV) isolates may yield variants
with improved properties for clinical applications. We generated a panel of synthetic AAV2
vectors by replacing a hexapeptide sequence in a previously identified heparan sulfate receptor
footprint with corresponding residues from other AAV strains. This approach yielded several
chimeric capsids displaying systemic tropism after intravenous administration in mice. Of
particular interest, an AAV2/AAV8 chimera designated AAV2i8 displayed an altered antigenic
profile, readily traversed the blood vasculature, and selectively transduced cardiac and whole-body
skeletal muscle tissues with high efficiency. Unlike other AAV serotypes, which are preferentially
sequestered in the liver, AAV2i8 showed markedly reduced hepatic tropism. These features of
AAV2i8 suggest that it is well suited to translational studies in gene therapy of musculoskeletal
disorders.
New viral strains constantly evolve in nature through iterative mutagenesis1,2. The breadth
of tissue tropism displayed by various AAV isolates, such as AAV8 and AAV9, is beneficial
for gene transfer by systemic delivery3–6. In some cases, however, it would be desirable to
direct homing of AAV vectors to specific organs. All naturally occurring AAV serotypes
and variants tested to date have a propensity to accumulate within the liver, albeit with
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varying efficiency4. Consequently, strategies to redirect AAV capsids from the liver to
target organs would be very useful from a clinical standpoint. Tissue-specific promoters and,
more recently, microRNA-based gene regulation strategies, have been used to sharply
segregate gene expression patterns among different tissue types7,8. However, such
regulatory strategies do not preclude sequestration of AAV vector genomes in off-target
organs such as the liver after systemic administration.
To develop AAV vectors with improved tropism for clinical applications, we reengineered
the heparan sulfate receptor footprint on the AAV2 capsid surface using information
available from structural studies, including crystallographic data and cryo-electron
microscope analysis of AAV capsids and their cognate receptors9–12. The heparan sulfate
footprint on the AAV2 capsid consists of the basic amino acid residues R484, R487, K527,
K532, R585 and R588, which form a continuous basic patch10–12. R585 and R588, located
within the so-called GH loop, form the inner walls of the spikes located on the icosahedral
threefold axis (Fig. 1a), and other residues occupy the floor surrounding these regions12.
Mutation of either R585 or R588 disrupts the basic cluster and abolishes heparan sulfate
binding10,11.
Using site-directed mutagenesis, we substituted the hexapeptide motif 585-RGNRQA-590,
which contains R585 and R588, with corresponding amino acids from different AAV
serotypes and nonhuman primate isolates (Fig. 1b,c) to generate a series of AAV2 inner loop
(AAV2i) mutants. Earlier studies established that mutating R585 and/or R588 on the AAV2
capsid to C, M, A or E is sufficient to attenuate heparan sulfate binding10,11. In the current
study, AAV2i mutants containing Q, A, S or N in position 585 and T, N, A or G in position
588 were also unable to bind heparan sulfate under physiological conditions, as
demonstrated by affinity column binding assays (Supplementary Fig. 1). In general, titers of
all AAV2i mutants were similar to that of the parental AAV2, and their efficiency at
transducing various cell types in vitro was reduced by several orders of magnitude
(Supplementary Fig. 2).
Using live animal bioluminescence imaging, we studied vector biodistribution in normal
BALB/C mice after intravenous administration at low dosage. One week after
administration, most AAV2i mutants were deficient in transduction as evidenced by low
bioluminescent signal (Fig. 1b). A notable exception was AAV2i8, which displayed a
systemic transduction profile (Fig. 1b) regardless of the duration of gene expression or the
intravenous route of administration (tail or portal vein; Supplementary Fig. 3).
Based on the above observations with AAV2i8 containing a 585-QQNTAP-590 motif, we
tested several AAV2i mutants with 585-QXXTXP-590 or 585-NXXTXP-590 motifs derived
from other strains of AAV. AAV2i mutants with residues Q/N585, T588 and P590 showed
systemic transduction profiles similar to that of the AAV8 control (Fig. 1c). In contrast, the
AAV2 control showed a greater tropism for liver, as established earlier4. The higher
transduction efficiency of AAV2i8 compared with AAV2i10, AAV2i11, AAV2irh.2 and
AAV2irh.38 highlights the subtle synergy between residues within the hexapeptide motif in
conferring systemic tissue tropism. Notably, the 585-QQNTAP-590 motif did not result in
systemic tropism when incorporated into the corresponding region on AAV1 or AAV3
capsids (Supplementary Fig. 4). Taken together, these results highlight the complexity of the
structural coordinates required to attain an atypical systemic transduction profile.
To examine the surface footprint of AAV2i8, we generated model surface maps of this
mutant and of parental AAV2 and AAV8 capsids using stereographic roadmap projections,
which allow simultaneous projection of amino acids, charge distribution and capsid surface
topology onto a two-dimensional surface13. Substitution of 585-RGNRQA-590 with
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QQNTAP results in disruption of the continuous basic patch (blue residues) formed by the
cluster of arginine and lysine residues (Fig. 1d). In addition, our model of the AAV2i8
footprint shows an overall chimeric distribution of amino acid residues with respect to
AAV2 and AAV8 (refs. 9,14). The chimeric nature of AAV2i8 is corroborated in the
observation that these capsids were only modestly neutralized when exposed to anti-AAV2
serum or human serum (Supplementary Tables 1 and 2). Thus, reengineering receptor
footprints on AAV capsids can simultaneously alter antigenicity.
Based on its promising transduction profile, the lab-derived AAV2i8 strain was further
characterized. We quantified luciferase transgene expression and genome copy numbers in
cardiac, skeletal muscle and liver tissue lysates at 2 weeks after vector administration in
BALB/C mice. As shown in Figure 2a, AAV8 ubiquitously transduced muscle and liver
tissue with high efficiency, consistent with the systemic transduction profile in Figure 1c.
AAV2 also transduced liver preferentially, although less efficiently than AAV8, and showed
only modest transduction in muscle tissue. The chimeric AAV2i8 transduced cardiac and
skeletal muscle tissue with a high efficiency similar to that of AAV8 and was detargeted
from the liver. These findings were supported by data on biodistribution of vector genome
copies in muscle and liver tissues determined by Q-PCR (Fig. 2b). For AAV2 and AAV8,
high amounts of vector genome copies were recovered from liver compared with cardiac or
skeletal muscle. For AAV2i8, sequestration in liver was ~40-fold lower compared with
AAV2 or AAV8.
Further biodistribution studies confirmed the redirection of AAV2i8 from liver to muscle.
AAV2i8 transduced a wide range of muscle groups in the murine forearms and hind legs as
well as intercostal, facial and abdominal muscles (Fig. 2c). Cardiac and diaphragm muscle
were transduced with high efficiency, whereas low levels of vector genome copies were
recovered from other major organs, such as brain, lung and spleen. These results distinguish
the tissue tropism of the chimeric AAV2i8 capsid from that of any naturally occurring AAV
serotype or isolate characterized thus far (Supplementary Fig. 5).
Our results confirm previous findings that attenuation of heparin binding in general can
result in liver detargeting and systemic dissemination of AAV2-derived vectors. Earlier
studies demonstrated a strong correlation between heparin binding and liver tropism in the
case of AAV2 and AAV6 (refs. 10,15). Disruption of the basic receptor footprint through
mutagenesis of R585 and/or R588 residues (in AAV2) or K531 (in AAV6) attenuated
heparan sulfate binding, which correlated with decreased liver tropism10,15. In addition, it
was demonstrated that an R484E;R585E AAV2 mutant is detargeted from the liver and
retains the ability to transduce muscle tissue with modest efficiency, similar to the parental
AAV2 (ref. 16). Although the R484E;R585E AAV2 vector has not shown high transduction
efficiency in larger animal models17 or been compared directly with AAV8 or AAV9, these
early studies clearly show the potential to control tissue tropism by manipulating receptor-
binding domains. Recently, a novel AAV mutant with cardiac-specific transduction was
generated through directed evolution18. The laboratory-derived M41 clone displayed a
tenfold higher transduction efficiency in cardiac tissue compared with the liver. Whereas
similar trends were observed for several of our mutants, an important advantage of AAV2i8
and mutants with a 585-QXXTXP-590 motif is their ability to efficiently transduce not only
cardiac muscle but the entire range of muscle groups with a transduction efficiency 2–3
orders of magnitude higher than that observed in the liver (Fig. 2c and Supplementary Fig.
5). To our knowledge, such an efficient switch in tropism from liver to muscle has not been
demonstrated previously.
Next, we used an isolated hind limb perfusion technique19 to examine the efficiency with
which AAV2i8 traverses the blood vessel barrier. AAV2i8 transduced hind limb skeletal
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muscle as efficiently as AAV8 at low volume of injection, at moderate and high vector
dosage (Fig. 3a–c). At low vector dose, AAV8 displayed three- to tenfold increases in
transduction efficiency at higher volumes of injection. However, AAV2i8 traversed blood
vessels and transduced underlying skeletal muscle with high efficiency regardless of the
volume of injection.
The atypical tropism of AAV2i8 distinguishes it from natural AAV serotypes 8 and 9 and
suggests that engineered AAV vectors can be tailored for specific clinical applications. The
mechanism underlying the switch in AAV2i8 tropism from liver to muscle is currently
unknown. Our results support the notion that the chimeric vector possesses a unique surface
footprint that facilitates specific interactions with receptors distinct from those used by
AAV2 and AAV8. Another possible explanation of our findings is that the increased
circulation half-life of AAV2i8 allows sequestration in tissues other than the liver through
heparan sulfate–independent uptake mechanisms. AAV2i8 showed markedly reduced blood
clearance and appears to persist well over 48 h in blood (Fig. 3d). Moreover, muscle-specific
luciferase transgene expression levels increased gradually over the course of several weeks
(Supplementary Fig. 6). In contrast, AAV8 vector genome copy number rapidly decreased,
approaching background levels within the same time period. These results and previous
observations that other AAV serotypes with systemic tissue tropism have long circulation
half-lives4 suggest that strategies to manipulate blood circulation time of AAV capsids
might afford control over vector tropism.
From the standpoint of vector development and clinical safety, AAV2i8 is an attractive
candidate for gene therapy of muscular dystrophies, which requires transduction of a wide
range of muscle types after systemic administration6,20. The selective muscle tropism of
AAV2i8 and its ability to evade sequestration by liver, when exploited in conjunction with
transcriptional regulatory elements such as muscle- specific promoters, should allow
exquisite control over vector biodistribution as well as cardiac or skeletal muscle–specific
transgene expression. Preliminary isolated limb perfusion studies in nonhuman primates
comparing AAV2i8 with AAV8 and AAV9 have shown promising results (data not shown)
in this regard.
In summary, we have developed a strategy to engineer synthetic AAV strains with atypical
transduction profiles. Extrapolation of this approach to receptor binding domains other than
the heparan sulfate binding domain and to other natural AAV isolates might yield new
chimeric vectors with unique tissue tropisms and antigenicity suitable for translational
disease-specific applications.
METHODS
Methods and any associated references are available in the online version of the paper at
http://www.nature.com/naturebiotechnology/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structure-function correlates of AAV2i vectors with reengineered receptor footprints. (a)
Three-dimensional structural model of the AAV2 capsid highlighting the 585–590 region
containing basic residues implicated in heparan sulfate binding. Inset shows VP3 trimer,
with residues 585-RGNRQA-590 located on the innermost surface loop highlighted in red.
VP3 monomers are colored salmon, blue, and gray. Images were rendered using Pymol. (b)
Representative live animal bioluminescent images of luciferase transgene expression
profiles in BALB/c mice (n = 3) injected intravenously (tail vein) with AAV2i CMV-Luc
vectors (dose 1 × 1010 vg in 200 µl PBS). Photographs and bioluminescent images were
obtained at 1 week after injection. The overlay demonstrates decreased transduction
efficiency for most AAV2i mutants with the exception of AAV2i8. Bioluminescence scale
ranges from 0–4 × 105 relative light units (photons/sec/cm2). Residues within the 585–590
region in each AAV2i mutant are indicated below corresponding mouse image data. (c)
Representative live animal bioluminescent images of luciferase transgene expression
profiles in BALB/c mice (n = 3) injected intravenously (tail vein) with AAV2, AAV8,
AAV2i8 and structurally related AAV2i mutants (dose 1 × 1011 vg in 200 µl PBS)
packaging the CBA (chicken beta actin)-Luc cassette. All AAV2i mutants show a systemic
transduction profile similar to that of AAV8, with AAV2i8 showing enhanced transduction
efficiency. Bioluminescence scale ranges from 0–3 × 106 relative light units (photons/sec/
cm2). Residues within 585–590 region in each AAV2i mutant is indicated below
corresponding mouse image data. (d) Comparison of AAV2, AAV2i8 and AAV8 capsid
surface residues based on schematic “Roadmap” projections. A section of the asymmetric
unit surface residues on the capsid crystal structures of AAV2 and AAV8, as well as a
model of AAV2i8, are shown. Close-up views of the heparan sulfate binding region and
residues 585–590 reveal a chimeric footprint on the AAV2i8 capsid surface. Red, acidic
residues; blue, basic residues; yellow, polar residues; green, hydrophobic residues. Each
residue is shown with a black boundary and labeled with VP1 numbering based on the
AAV2 capsid protein sequence.
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Selective muscle tropism of AAV2i8. (a) Quantification of luciferase transgene expression
in three major tissues: cardiac (black bars), skeletal muscle (pooled hind limb and
abdominal; gray bars) and liver (white bars). Tissue lysates were obtained from BALB/c
mice (n = 3) at 2 weeks after administration of AAV2, AAV2i8 and AAV8 (dose 1 × 1011
vg, tail vein) and subjected to luminometric analysis. AAV2i8 shows high transduction in
cardiac and skeletal muscle and low transduction in liver. Luciferase levels are shown as
relative light units normalized to protein levels determined using a Bradford assay. Error
bars indicate s.d. (b) Vector genome copy numbers (luciferase transgene) in three major
tissues: cardiac (black bars), skeletal muscle (pooled hind limb and abdominal; gray bars)
and liver (white bars). Host genomic as well vector DNA was extracted from tissue lysates
obtained from BALB/c mice (n = 3) at 2 weeks after administration of AAV2, AAV2i8 and
AAV8 (dose 1 × 1011 vg, tail vein). Host and vector genome copy number were determined
by Q-PCR with specific primer sets against the lamin gene and luciferase transgene,
respectively. AAV2i8 shows enhanced muscle sequestration and decreased accumulation in
liver tissue compared with AAV2 and AAV8. (c) Luciferase transgene expression in major
muscle sub-groups obtained from BALB/c mice (n = 3) at 2 weeks after intravenous
administration of AAV2i8 (dose 1 × 1011 vg, tail vein) packaging the CBA (chicken beta
actin)-Luc cassette. Tissue lysates from five different muscle groups from the hind limb
skeletal muscle (alternating black and white bars), three groups from the forelimb
(alternating black and white bars), intercostals, cardiac, facial, diaphragm, tongue,
abdominal and vertebral muscle types (black bars) were subjected to luminometric analysis.
Luciferase levels are shown as relative light units normalized to protein levels determined by
a Bradford assay. Error bars indicate s.d.
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Blood transport profile of AAV2i8. (a–c) Luciferase transgene expression in pooled skeletal
muscle subgroups from right and left hind limb of BALB/c mice (n = 4) after isolated
perfusion of AAV2i8 (black bars) or AAV8 (gray bars) into each saphenous vein. Tissue
lysates prepared after administration of three different doses (1 × 109 (a), 1 × 1010 (b), 1 ×
1011 (c) vg) in low (200 µl), medium (500 µl) or high (1 ml) volume of injection were
subjected to luminometric analysis. Luciferase levels are shown as relative light units
ormalized to protein levels determined using a Bradford assay. (d) Vector genome copy
numbers recovered from blood at different time intervals after administration through the
tail vein (n = 3). Whole blood DNA was extracted and analyzed by Q-PCR with primers
against the luciferase transgene. AAV2i8 shows prolonged circulation compared with
AAV8. Error bars indicate s.d.
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